Have your own idea? Try our Stock Screener
U.S. Biotech Industry Analysis
UpdatedAug 17, 2025
DataAggregated Company Financials
Companies551
- 7D4.5%
- 3M12.0%
- 1Y-5.3%
- YTD6.5%
In the last week, the Biotech industry is up 4.5%, with AbbVie up 4.4%. In the same time, Summit Therapeutics was down 6.9%. However, the industry is down 5.3% over the past year. Looking forward, earnings are forecast to grow by 26% annually.
Industry Valuation and Performance
Has the U.S. Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sun, 17 Aug 2025 | US$1.1t | US$163.6b | -US$18,739,718,949.95 | 15.6x | -57.4x | 6.6x |
| Tue, 15 Jul 2025 | US$974.2b | US$155.8b | -US$23,412,837,702.48 | 18x | -41.6x | 6.3x |
| Thu, 12 Jun 2025 | US$959.4b | US$155.9b | -US$23,944,577,514.84 | 16.9x | -40.1x | 6.2x |
| Sat, 10 May 2025 | US$879.4b | US$154.9b | -US$24,542,496,165.11 | 16.7x | -35.8x | 5.7x |
| Mon, 07 Apr 2025 | US$735.9b | US$118.6b | -US$37,018,260,571.73 | 20.1x | -19.9x | 6.2x |
| Wed, 05 Mar 2025 | US$831.7b | US$119.0b | -US$37,123,415,733.90 | 16.4x | -22.4x | 7x |
| Fri, 31 Jan 2025 | US$990.2b | US$149.5b | -US$26,311,030,486.43 | 17.4x | -37.6x | 6.6x |
| Sun, 29 Dec 2024 | US$977.8b | US$149.9b | -US$26,372,711,577.30 | 16.2x | -37.1x | 6.5x |
| Tue, 26 Nov 2024 | US$1.0t | US$150.0b | -US$26,579,608,946.27 | 16.4x | -38.2x | 6.8x |
| Thu, 24 Oct 2024 | US$897.0b | US$113.1b | -US$36,020,164,121.55 | 21x | -24.9x | 7.9x |
| Sat, 21 Sep 2024 | US$927.5b | US$113.2b | -US$35,987,032,000.31 | 21.9x | -25.8x | 8.2x |
| Mon, 19 Aug 2024 | US$883.2b | US$113.2b | -US$35,819,260,655.83 | 22.3x | -24.7x | 7.8x |
| Wed, 17 Jul 2024 | US$1.2t | US$164.5b | -US$28,050,454,935.07 | 29.4x | -42.6x | 7.3x |
| Fri, 14 Jun 2024 | US$1.2t | US$164.5b | -US$28,081,541,373.98 | 27.8x | -41.3x | 7.1x |
| Sun, 12 May 2024 | US$1.1t | US$164.6b | -US$26,967,551,943.98 | 23.3x | -41.2x | 6.7x |
| Tue, 09 Apr 2024 | US$1.1t | US$164.4b | -US$23,377,181,270.88 | 21x | -48.3x | 6.9x |
| Thu, 07 Mar 2024 | US$1.2t | US$167.9b | -US$21,278,119,441.95 | 16x | -55.9x | 7.1x |
| Sat, 03 Feb 2024 | US$1.4t | US$203.9b | -US$24,418,168,728.00 | 19.2x | -58.9x | 7.1x |
| Mon, 01 Jan 2024 | US$1.4t | US$204.9b | -US$22,199,078,413.00 | 19.8x | -62.6x | 6.8x |
| Wed, 29 Nov 2023 | US$1.2t | US$204.8b | -US$22,005,071,481.00 | 17.8x | -55.6x | 6x |
| Fri, 27 Oct 2023 | US$1.2t | US$207.5b | -US$12,993,510,910.00 | 16.8x | -93.2x | 5.8x |
| Sun, 24 Sep 2023 | US$1.3t | US$207.5b | -US$12,879,333,723.00 | 17.1x | -97.9x | 6.1x |
| Tue, 22 Aug 2023 | US$1.3t | US$207.6b | -US$12,363,308,148.00 | 17.5x | -102.3x | 6.1x |
| Thu, 20 Jul 2023 | US$1.1t | US$186.6b | -US$15,972,272,220.00 | 12.8x | -71.5x | 6.1x |
| Sat, 17 Jun 2023 | US$1.2t | US$186.3b | -US$16,045,332,946.00 | 12.1x | -72.3x | 6.2x |
| Mon, 15 May 2023 | US$1.2t | US$191.7b | -US$12,222,188,637.00 | 13.8x | -94.5x | 6x |
| Wed, 12 Apr 2023 | US$1.2t | US$198.3b | -US$3,303,389,351.00 | 13.9x | -351.9x | 5.9x |
| Fri, 10 Mar 2023 | US$1.1t | US$199.1b | -US$4,987,732,730.00 | 15x | -221x | 5.5x |
| Sun, 05 Feb 2023 | US$1.2t | US$203.6b | US$1.6b | 15.6x | 711.4x | 5.7x |
| Tue, 03 Jan 2023 | US$1.2t | US$203.5b | US$1.7b | 14.3x | 667.4x | 5.7x |
| Thu, 01 Dec 2022 | US$1.2t | US$202.3b | US$1.3b | 15.1x | 918x | 5.7x |
| Sat, 29 Oct 2022 | US$1.1t | US$205.9b | US$7.4b | 14.3x | 148.7x | 5.3x |
| Mon, 26 Sep 2022 | US$1.0t | US$206.0b | US$5.6b | 13.9x | 182.3x | 4.9x |
| Wed, 24 Aug 2022 | US$1.1t | US$206.3b | US$7.3b | 15.8x | 146.5x | 5.2x |
Price to Earnings Ratio
146.5x
Current Industry PE
- Investors are relatively neutral on the American Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.
- The industry is trading close to its 3-year average PS ratio of 6.4x.
Past Earnings Growth
- Total earnings for the Biotechs industry have declined over the last three years, with the industry now making a loss overall.
- Revenues have also declined 7.4% per year, which is driving profits down.
Industry Trends
Which industries have driven the changes within the U.S. Healthcare industry?
| US Market | 1.05% | |
| Healthcare | 4.95% | |
| Biotech | 4.51% | |
| Biotech | 4.51% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| ABBV AbbVie | US$206.69 | 4.4% +US$15.3b | 6.6% | PE98.1x | |
| VRTX Vertex Pharmaceuticals | US$392.79 | 7.2% +US$6.7b | -17.7% | PE27.7x | |
| AMGN Amgen | US$296.47 | 2.9% +US$4.4b | -7.8% | PE24.1x | |
| INSM Insmed | US$127.80 | 16.7% +US$3.9b | 67.7% | PS67.9x | |
| ONC BeOne Medicines | US$321.36 | 11.5% +US$3.7b | 65.1% | PS7.8x |
